Scarica l'app Stockscreener
25.61
1.08%
-0.28
Dopo l'orario di chiusura:
25.29
-0.32
-1.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
The Zacks Analyst Blog Highlights CVS Health, Cardinal Health, Humana and ACADIA Pharmaceuticals - Yahoo Finance
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals - Yahoo! Finance Canada
Is ACADIA Pharmaceuticals (ACAD) A Bargain On Fast Track News And Trial Timing? - Sahm
4 Medical Stocks With the Right Setup for Q2 Earnings Beats - TradingView
Acadia Pharmaceuticals: Why I'm Bullish Ahead Of The RADIANT Readout (NASDAQ:ACAD) - Seeking Alpha
ACADIA Pharmaceuticals Inc (ACAD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ACAD|ACADIA Pharmaceuticals Inc|Price:24.840|Chg%:+0.010 - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Cash Flow - TradingKey
Stifel Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Raises Target Price to $25 - Moomoo
ACAD: Acadia Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
ACADIA Pharmaceuticals Inc. (ACAD) stock price, news, quote and history - Yahoo Finance Singapore
ACADIA Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History - Yahoo! Finance Canada
ACADIA Pharmaceuticals Inc (ACAD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Mizuho Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Acadia gains fast track status for remlifanserin in Alzheimer's disease psychosis - MSN
Mizuho Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate - TradingView
ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: Exploring a 30% Potential Upside Amid Robust Growth - DirectorsTalk Interviews
Mizuho reiterates Acadia stock rating on Alzheimer’s trial progress - Investing.com UK
Stifel raises Acadia Pharmaceuticals price target on drug potential By Investing.com - Investing.com South Africa
Stifel raises Acadia Pharmaceuticals price target on drug potential - Investing.com
Acadia Pharmaceuticals (ACAD) Receives FDA Fast Track for Remlif - GuruFocus
Lobbying Update: $700,000 of ACADIA PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis - BioSpace
ETFs Investing in ACADIA Pharmaceuticals Inc. Stocks - TradingView
JP Morgan Maintains ACADIA Pharmaceuticals (ACAD) Overweight Recommendation - MSN
ACADIA Pharmaceuticals (ACAD) Stock Trades At A Discount To Earnings But Faces Concentrated Risk - webull.com
ACADIA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GAROFALO ELIZABETH A.moomoo - Moomoo
Understanding the Setup: (ACAD) and Scalable Risk - Stock Traders Daily
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 - BioSpace
Bank of America Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Press Release: Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 - Moomoo
Acadia Pharmaceuticals to announce Q2 2026 results on August 4 - scanx.trade
Acadia to Host Q2 Results Call After Markets Close Aug. 4 - Stock Titan
BofA Securities Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $30 - Moomoo
ACADIA Pharmaceuticals Inc (ACAD) Institutional Confidence - TradingKey
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors? - The Motley Fool
Acadia rises as EU backs Rett syndrome therapy - MSN
ACADIA Pharmaceuticals (ACAD) Names A New Chief People Officer, Is It Still Below Fair Value? - Yahoo Finance
Why Acadia Pharmaceuticals stock is soaring today - MSN
ACADIA Pharmaceuticals (ACAD) Stock Looks Undervalued After A 21% Run - Sahm
Is ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win? - Yahoo Finance
Is ACADIA Pharmaceuticals (ACAD) Undervalued On Rett Progress And Its Leadership Change? - simplywall.st
How CHMP’s Positive Rett Syndrome Ruling on DAYBU Could Impact ACADIA Pharmaceuticals (ACAD) Investors - Yahoo Finance
H.C. Wainwright Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Carl Segerstrom Appointed Chief People Officer at Acadia Pharmaceuticals - hrtoday.in
Should EMA’s Positive Rett Syndrome Opinion for DAYBU Reshape ACADIA Pharmaceuticals’ (ACAD) Investment Narrative? - Sahm
1.84%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):